RecruitingPhase 1NCT02287428

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
David A. Reardon, MD
Dana-Farber Cancer Institute
Intervention
Radiation Therapy(radiation)
Enrollment
56 enrolled
Eligibility
18 years · All sexes
Timeline
20142028

Study locations (2)

Collaborators

The Ben & Catherine Ivy Foundation · Accelerate Brain Cancer Cure · Merck Sharp & Dohme LLC · National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02287428 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials